An Industry-Leading Clinical and Preclinical CRO With a Solid Reputation

MicroConstants is a GLP-compliant clinical and preclinical CRO (Contract Research Organization) focused on performing regulated bioanalysis, drug metabolism, and pharmacokinetic analysis in support of discovery, preclinical, and clinical drug development studies. We provide highly specialized services in method development, validation, and sample analysis for small molecules, macromolecules, biomarkers, and metabolites, using LC/MS/MS, HPLC/UV, immunoassay, multiplex, and qPCR techniques. We also assemble and distribute protocol-specific specimen collection kits to streamline and simplify the PK collection process for single and multi-site clinical trials.

Our Story

MicroConstants, Inc. was founded in 1998 in San Diego, California, by Gilbert Lam, Ph.D., a veteran in pharmaceutical development and a scientist trained in the field of pharmacokinetics. Our San Diego facility has since grown to become one of the largest bioanalytical LC/MS/MS laboratories in the U.S., housing 25 LC/MS/MS systems and occupying 34,000 square feet of office and laboratory space.

In 2021, MicroConstants was acquired by BioAgilytix, a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area, the Cambridge area of Massachusetts, and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. MicroConstants will be known as BioAgilytix San Diego post acquisition and integration. Through the acquisition, BioAgilytix gains small molecule LC/MS/MS capabilities, specialized DMPK assay capabilities and additional large molecule capacity along with a physical location on the West Coast.

MicroConstants by the Numbers

The numbers are clear: MicroConstants is a highly reputable, experienced partner for regulated
bioanalysis studies.

100% program approval rate by USFDA

0

regulatory complaints
over 4 FDA audits

6300

+

regulated studies
supported

20

+

years experience

50

%

of company resources
dedicated to lab

2400

+

methods developed

1500

+

validated assays